- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Stiefel Laboratories to acquire Barrier Therapeutics
Coral Gables, Fla. - Stiefel Laboratories has announced it has signed a definitive merger agreement to acquire Barrier Therapeutics, according to PRNewswire.
Coral Gables, Fla.
- Stiefel Laboratories has announced it has signed a definitive merger agreement to acquire Barrier Therapeutics, according to PRNewswire.
The transaction is valued at approximately $148 million, and is subject to valid tender of a majority of Barrier Therapeutics' fully diluted common stock, regulatory approvals and other customary conditions.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Weighing In on Biologics and JAK Inhibitors for Atopic Dermatitis
LEVEL UP Trial Sets New Benchmark for Atopic Dermatitis Treatment
How OX40-Targeted Therapies Might Reshape Biologic Strategy in AD
Expanding Topical Non-Steroidal Options in Atopic Dermatitis to Reduce Chronic Steroid Use
Understanding the Role of OX40 in Next-Generation Eczema Therapies
Jonathan Silverberg, MD, PhD, MPH on Keeping Up With Rapid AD Developments
The Vicious Cycle of Itch, Stress, and Sleep Loss
Christopher Bunick, MD, PhD, Previews RAD 2025: Raising the Bar in Atopic Dermatitis Care
Current Unmet Needs and Emerging Solutions in Atopic Dermatitis Management
Implementation Factors Affecting Ruxolitinib Adoption in Pediatric Dermatology Practice
Related Content
